References
- Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J, et al. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a pop-5. ulation-based study. The Lancet Respiratory Medicine. 2025;I3: 348-363. doi:10.1016/S2213-2600(24)00428-4
- Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. Journal of Thoracic Oncology. 2022;17: 362-387. doi:10.1016/j.jtho.2021.11.003
- Chang WC, Zhang YZ, Nicholson AG. Pulmonary invasive mucinous adenocarcinoma. Histopathology. 2024;84: 18-31. doi:10.1111/his.15064
- Zhao T, Yi J, Luo D, Liu J, Fan X, Wu Q, et al. Prognostic factors for invasive mucinous adenocarcinoma of the lung: systematic review and meta-analysis. World Journal of Surgical Oncology. 2024;22: 41. doi:10.1186/s12957-024-03326-4
- Huo JW, Huang XT, Li X, Gong JW, Luo TY, Li Q. Pneumonictype lung adenocarcinoma with different ranges exhibiting different clinical, imaging, and pathological characteristics. Insights into Imaging. 2021;12: 169. doi:10.1186/s13244-021-01114-2